10,470 million baht or 11% of total accounts receivable, comparing to that of 10,951 million baht or 12% of total accounts receivable at the end of previous fiscal year. The delinquent account receivables
reduction in personal loan receivable by 517 million baht or 1% from end of last fiscal year. The main assets were attributed to the portfolio of net account receivables which shared 99% of total assets
controlling process in production and better efficiency in production line. 3. Selling expenses For Quarter 2 of the year 2020, the selling expenses was 2.66 million baht or 2.66% from sale revenue compare to
recorded an average production rate of 118. 82 KBD (99% utilization rate) which is considered as a record all-time high for average production rate in any quarter in the history of the Bangchak refinery
IP_AC/001/2563 February 24, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited
, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited ( “ the Company” ) would like
cost was 10.05 Million Baht or an increase of 7.18 Million Baht which is equivalent to an increase of 250.17 % from the previous year. For the period of six months of the fiscal year 2017, the Company's
year. For the period of nine months of the fiscal year 2017, the Company's financing cost was 42.48 Million Baht, increased by 32.67 Million Baht, or up by 333.03% from the previous year. The result was
machinery, equipment and related expenses to increase the production capacity of the flexible packaging products another Baht 40 million. This is to increase the proportion of high gross margin products. In